AKT1 and Familial prostate cancer: In particular, in androgen-dependent and -independent prostate carcinoma, NT157 decreases the expression of IRS proteins and downregulates IGF-1R-mediated AKT activation, leading to cell cycle arrest, apoptosis, and a delay of castrate-resistant prostate cancer progression in xenografts (28).